(Q34459409)

2 August 2017

1 reference

title

Resistance and cross-resistance to abacavir (English)

1 reference

2 August 2017

1 reference

G Moyle

1

1 reference

2 August 2017

language of work or name

1 reference

1 July 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

2

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

154-162

1 reference

Viral dynamics in human immunodeficiency virus type 1 infection

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00069.X

10.1046/J.1468-1293.2001.00069.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference